Executive Chair share purchase

Summary by AI BETAClose X

EKF Diagnostics Holdings plc announced that its Executive Chair, Julian Baines, purchased 85,000 ordinary shares at 23.0 pence per share on December 15, 2025. Following this transaction, Mr. Baines now holds 1,751,288 ordinary shares, representing approximately 0.40% of the company's issued share capital. This purchase by a key executive could be viewed positively by the market as a sign of confidence in the company's future prospects.

Disclaimer*

EKF Diagnostics Holdings PLC
16 December 2025
 

EKF Diagnostics Holdings plc

("EKF" or the "Company")

 

Executive Chair share purchase

 

EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed global diagnostics business, announces that on Monday 15 December, Julain Baines, Executive Chair, purchased a total of 85,000 ordinary shares of 1 pence each in the Company ("Ordinary Shares") at a price of 23.0 pence per Ordinary Share.

 

Following this transaction, Julian Baines' total interest in the Company is 1,751,288 Ordinary Shares, representing approximately 0.40% of the total voting rights over the Company's issued share capital.

 

The Notification of Dealing Form required in accordance with UK MAR is set out below as is the Standard form for notification of major holdings received by EKF today.

 

EKF Diagnostics Holdings plc

www.ekfdiagnostics.com

Julian Baines, Executive Chair

 Via Walbrook PR

Gavin Jones, Chief Executive Officer

 


Tel: +44 (0)20 7496 3000

Singer Capital Markets (Nominated Adviser & Broker)

 

Phil Davies / Oliver Platts




Walbrook PR Limited

Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com

Paul McManus / Alice Woodings

Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654

 

A white machine next to a blue device AI-generated content may be incorrect.

 

 

About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com)

 

EKF is an AIM-listed global diagnostics business focussed on:

 

·    Point-of-Care analysers in the key areas of Hematology and Diabetes.

·    Life Sciences services provide specialist manufacture of enzymes and custom products for use in diagnostic food and industrial applications.

 

EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing sites across the US and Germany, selling into over 120 countries world-wide.



 

 

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

 Julian Baines

2

 

Reason for the notification

 

a)

 

Position/status

 

 

Executive Chair

b)

 

Initial notification /Amendment

 

 

Initial Notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

EKF Diagnostics Holdings plc

b)

 

LEI

 

 

213800DXTF3EAUK1AR05

 

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

Ordinary shares of 1 pence each



Identification code

GB0031509804

 



b)

 

Nature of the transaction

 

 

Purchase of Ordinary Shares

c)

 

Price(s) and volume(s)







Price(s)

Volume(s)




23p

85,000







d)

 

Aggregated information




- Aggregated volume

N/A single transaction



- Price




e)

 

Date of the transaction

 

 

 15 December 2025

f)

 

Place of the transaction

 

 

London Stock Exchange, AIMX




 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100

Latest directors dealings